A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective real-world study. In this study, we plan to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab .

Detailed Description
-----------------
This study is a retrospective real-world study. The diagnosis and treatment of patients, disease management, and information collection are completely dependent on the daily medical practice. In this study, we plan to select 5 to 8 hospitals nationwide to collect the clinical data of LASCCHN patients who received chemoradiotherapy combined with or without nimotuzumab from January 2015 to December 2018. Patients included in the study will be followed up for survival. The main endpoint is 3-year overall survival (OS) rate; the secondary endpoint are 3-year progression-free survival (PFS) rate, 3-year Local-regional control (LRC) rate, objective response rate (ORR), disease control rate (DCR) and safety.

Official Title
-----------------
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Conditions
-----------------
Locally Advanced Head and Neck Squamous Cell Carcinoma

Intervention / Treatment
-----------------
* Drug: nimotuzumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years old, no gender limitation; Histopathologically or cytologically proved to be phase III-IVb of head and neck squamous cell carcinomas (including oral cancer, oropharynx cancer, hypopharynx cancer, larynx cancer, but except for nasopharyngeal carcinoma). Patients who received chemoradiotherapy combined with or without nimotuzumab from January 2015 to December 2018; Patients in the study group received nimotuzumab, while patients in the control group did not receive nimotuzumab. And patients in the control group were collected 3 times as many cases as the study group in each center. If the number of patients in the control group were less than 3 times of the study group, all cases were collected. Exclusion Criteria: Complicated with primary malignancies other than head and neck tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix); Patients received other targeted therapy, immunotherapy, or Traditional Chinese medicine with anti-tumor effect, along with the application of nimotuzumab; Lack of critical evaluation information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| study group<br>Patients of study group were all treated with chemoradiotherapy plus nimotuzumab. | Drug: nimotuzumab<br>* Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).<br>* Other names: chemoradiotherapy;|
| control group<br>Patients of control group were only treated with chemoradiotherapy, and were collected at least 3 times as many patients as the study group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-year overall survival (OS) rate | 3-year overall survival (OS) rate | Up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-year progression-free survival (PFS) rate | 3-year progression-free survival (PFS) rate | Up to 3 years | 
| 3-year Local-regional control (LRC) rate | 3-year Local-regional control (LRC) rate | Up to 3 years | 
| objective response rate (ORR) | objective response rate (ORR)=CR+PR | Up to 12 months | 
| disease control rate (DCR) | disease control rate (DCR) | Up to 12 months | 
| Safety as measured by number and grade of adverse events | Classification, frequency, and severity of drug-related adverse events | Up to 3 years |